U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Size, Share, Industry Analysis Report By Type [Transurethral Resection of Prostate (TURP), Prostatic Urethral Lift], By End User– Market Forecast, 2025–2034
Description
The U.S. benign prostatic hyperplasia surgical treatment market size is expected to reach USD 1,232.65 million by 2034, according to a new study by Polaris Market Research. The report “U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Share, Size, Trends, Industry Analysis Report By Type [Transurethral Resection of Prostate (TURP), Prostatic Urethral Lift], By End User; Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Benign prostatic hyperplasia surgical treatment refers to clinically guided procedures aimed at relieving urinary symptoms associated with prostate gland enlargement in aging men. The growing preference for outpatient and minimally invasive surgery approaches, which offer shorter hospital stays and quicker recovery times, is driving market growth. This shift is driven by growing patient awareness, payer support for cost-effective interventions, and the healthcare system’s focus on enhancing procedural efficiency. As a result, there is a growing acceptance of advanced surgical techniques that balance clinical outcomes and patient comfort.
The rapid integration of advanced technologies drives the U.S. BPH surgical treatment market, supporting precision and consistency in surgical care. Innovations in urology tools, real-time imaging, surgical robot, and energy-based devices are streamlining treatment workflows and improving patient outcomes. These technological advancements are encouraging the adoption of evidence-based practices and personalized care strategies, reinforcing the market’s shift toward high-value, outcome-oriented healthcare delivery.
U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Report Highlights
In terms of type, the transurethral resection of the prostate (TURP) segment led the U.S. benign prostatic hyperplasia surgical treatment market in 2024, owing to its proven clinical effectiveness and established role as the standard treatment for BPH.
Based on end user, the ambulatory surgery centers (ASCs) segment is expected to achieve the highest CAGR during the forecast period, driven by increasing demand for outpatient procedures and cost-efficient healthcare delivery.
A few market players include Boston Scientific Corporation; Cleveland Clinic; Cook Medical; Eli Lilly and Company; Medifocus, Inc.; Medtronic; PROCEPT BioRobotics Corporation; Teleflex Incorporated; The Johns Hopkins Hospital; and Viatris Inc.
Polaris Market Research has U.S. Benign Prostatic Hyperplasia Surgical Treatment Market segmented the market report on the basis of type and end user:
By Type Outlook (Revenue, USD Million, 2020–2034)
Transurethral Resection of the Prostate (TURP)
Prostatic Urethral Lift
Water Vapor Therapy
Laser Therapy
Aquablation Therapy
Transurethral Microwave Thermotherapy (TUMT)
Others
By End User Outlook (Revenue, USD Million, 2020–2034)
Hospitals
Ambulatory Surgery Centers and Clinics
Homecare Settings
Benign prostatic hyperplasia surgical treatment refers to clinically guided procedures aimed at relieving urinary symptoms associated with prostate gland enlargement in aging men. The growing preference for outpatient and minimally invasive surgery approaches, which offer shorter hospital stays and quicker recovery times, is driving market growth. This shift is driven by growing patient awareness, payer support for cost-effective interventions, and the healthcare system’s focus on enhancing procedural efficiency. As a result, there is a growing acceptance of advanced surgical techniques that balance clinical outcomes and patient comfort.
The rapid integration of advanced technologies drives the U.S. BPH surgical treatment market, supporting precision and consistency in surgical care. Innovations in urology tools, real-time imaging, surgical robot, and energy-based devices are streamlining treatment workflows and improving patient outcomes. These technological advancements are encouraging the adoption of evidence-based practices and personalized care strategies, reinforcing the market’s shift toward high-value, outcome-oriented healthcare delivery.
U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Report Highlights
In terms of type, the transurethral resection of the prostate (TURP) segment led the U.S. benign prostatic hyperplasia surgical treatment market in 2024, owing to its proven clinical effectiveness and established role as the standard treatment for BPH.
Based on end user, the ambulatory surgery centers (ASCs) segment is expected to achieve the highest CAGR during the forecast period, driven by increasing demand for outpatient procedures and cost-efficient healthcare delivery.
A few market players include Boston Scientific Corporation; Cleveland Clinic; Cook Medical; Eli Lilly and Company; Medifocus, Inc.; Medtronic; PROCEPT BioRobotics Corporation; Teleflex Incorporated; The Johns Hopkins Hospital; and Viatris Inc.
Polaris Market Research has U.S. Benign Prostatic Hyperplasia Surgical Treatment Market segmented the market report on the basis of type and end user:
By Type Outlook (Revenue, USD Million, 2020–2034)
Transurethral Resection of the Prostate (TURP)
Prostatic Urethral Lift
Water Vapor Therapy
Laser Therapy
Aquablation Therapy
Transurethral Microwave Thermotherapy (TUMT)
Others
By End User Outlook (Revenue, USD Million, 2020–2034)
Hospitals
Ambulatory Surgery Centers and Clinics
Homecare Settings
Table of Contents
129 Pages
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
